Filana Therapeutics, Inc.
filanatx.comWhat Do They Do?
Develops simufilam, an oral drug candidate for TSC-related epilepsy and other disorders associated with filamin A, for patients with central nervous system disorders.
10-K for FY2025, filed Mar 12, 2026Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission…View ↗
Our lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of…View ↗
Simufilam is intended to modulate the activity of a protein called filamin A, which regulates diverse aspects of neuronal cell development.…View ↗
Who Are Their Customers?
No customers described: the company is developing drug candidates and has no approved products.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 29, 2026
−$8.6MView ↗
- ▼ −81% (Loss)
- vs −$44.2M in Q2 FY2025
From Alzheimer’s to TSC epilepsy
The older report described simufilam as being developed for Alzheimer’s disease and also listed a blood-based Alzheimer’s diagnostic candidate. The latest report focuses on simufilam for TSC-related epilepsy and says the Alzheimer’s program has been discontinued.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 12, 2026Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat…View ↗
We currently have two biopharmaceutical assets under development:View ↗
our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer’s disease from a…View ↗
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission…View ↗
Our lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of…View ↗
With the failure of both trials to meet their efficacy endpoints, we announced the decision to phase out our Alzheimer’s disease…View ↗
Who Do They Compete With?
Competes with Afinitor Disperz and Epidiolex
10-K for FY2025, filed Mar 12, 2026With respect to TSC-related epilepsy, two pharmacological treatment categories are approved for this patient population. The first category…View ↗
Loading...
